Advertisement
Screener

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Deferred Compensation Equity

2.8 / 5 stars · 68/120 Roast Me

CERO THERAPEUTICS HOLDINGS, INC. Deferred Compensation Equity

CERO THERAPEUTICS HOLDINGS, INC. (CERO) had Deferred Compensation Equity of $69.10 thousand as of 2026-03-04, per its 10-Q filed 2026-08-14.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent

us-gaap:DeferredCompensationEquity · last filed 2026-08-14

  • 2026-03-04: Deferred Compensation Equity $69.10K.
  • 2025-05-30: Deferred Compensation Equity $351.86K.
  • 2025-03-04: Deferred Compensation Equity $488.72K.
Period endDeferred Compensation Equity
2026-03-04$69.10K
10-Q · filed 2026-08-14
2025-05-30$351.86K
10-K · filed 2026-04-15
2025-03-04$488.72K
10-K · filed 2026-04-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
AIM ImmunoTech Inc. (AIM)United States$0.006B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
IN8BIO, INC. (INAB)United States$0.012B-0.76
CURIS INC (CRIS)United States$0.002B-0.05